Description

Selank is a synthetic peptide developed in Russia with notable potential for therapeutic use, particularly in the realms of anxiety reduction and cognitive enhancement. This peptide is a modified version of tuftsin, a naturally occurring peptide involved in immune regulation. Selank’s mechanism of action is believed to involve the modulation of key neurotransmitter systems, particularly serotonin and dopamine, which play crucial roles in mood regulation and cognitive functions. By influencing these neurotransmitter systems, Selank aims to stabilize mood, reduce anxiety, and enhance overall cognitive performance. Its impact on serotonin helps regulate mood and emotional stability, while its effects on dopamine can support improved cognitive function and focus. This dual modulation is thought to contribute to Selank’s effectiveness in managing stress and improving mental well-being. (1,2,3)

Selank is commonly employed in the management of stress-related conditions and is considered a promising treatment for generalized anxiety disorder (GAD). (4) Unlike traditional anxiolytics, Selank does not produce sedative or muscle-relaxant effects, making it a favorable option for those seeking relief from anxiety without compromising alertness or daily functioning. Its unique profile, including its potential to improve cognitive performance while alleviating anxiety, positions Selank as a valuable therapeutic agent for individuals experiencing chronic stress and anxiety disorders.

(1) Kasian, A., Kolomin, T., Andreeva, L., Bondarenko, E., Myasoedov, N., Slominsky, P., & Shadrina, M. (2017). Peptide Selank enhances the effect of diazepam in reducing anxiety in unpredictable chronic mild stress conditions in rats. Behavioural Neurology, 2017(1), 5091027.

(2) Koroleva, S. V., & Mjasoedov, N. F. (2019). Physiological effects of Selank and its fragments. Biology Bulletin, 46(4), 407-414.

(3) Sollertinskaya, T. N., Shorokhov, M. V., Kozlovskaya, M. M., Kozlovskii, I. I., & Sudakov, K. V. (2008). Compensatory and antiamnestic effects of heptapeptide Selank in monkeys. Journal of Evolutionary Biochemistry and Physiology, 44, 332-340.

(4) Volkova, A., Shadrina, M., Kolomin, T., Andreeva, L., Limborska, S., Myasoedov, N., & Slominsky, P. (2016). Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Frontiers in pharmacology, 7, 31. https://doi.org/10.3389/fphar.2016.00031

Additional information